Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population

Affiliations

¹ Department of Dermatology, University of Tsukuba, Japan.
² Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
³ Department of Dermatology, Kyoto University, Kyoto, Japan.
⁴ Department of Dermatology, Keio University, Tokyo, Japan.
⁵ Department of Dermatology, Tohoku University, Sendai, Japan.
⁶ Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
⁷ Department of Dermatology, Hokkaido University, Sapporo, Japan.
⁸ Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.

Y Fujisawa et al. Br J Dermatol. 2018 Jul.

. 2018 Jul;179(1):213-215.

doi: 10.1111/bjd.16427. Epub 2018 Apr 24.

¹ Department of Dermatology, University of Tsukuba, Japan.
² Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
³ Department of Dermatology, Kyoto University, Kyoto, Japan.
⁴ Department of Dermatology, Keio University, Tokyo, Japan.
⁵ Department of Dermatology, Tohoku University, Sendai, Japan.
⁶ Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
⁷ Department of Dermatology, Hokkaido University, Sapporo, Japan.
⁸ Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.

No abstract available

Comment in

Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors.
Machet L, Zaragoza J, Finon A, Garnier M, Maillard H, Caille A. Machet L, et al. Br J Dermatol. 2018 Jul;179(1):224. doi: 10.1111/bjd.16675. Epub 2018 May 8. Br J Dermatol. 2018. PMID: 29660775 No abstract available.
Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors.
Fujisawa Y. Fujisawa Y. Br J Dermatol. 2018 Jul;179(1):224-225. doi: 10.1111/bjd.16689. Epub 2018 May 7. Br J Dermatol. 2018. PMID: 29733122 No abstract available.